Results 91 to 100 of about 1,772,527 (156)

Hypomethylating agent based combinations in higher risk myelodysplastic syndrome

open access: yes, 2019
For over a decade the hypomethylating agents (HMA) azacitidine and decitabine have been the mainstay of therapy for myelodysplastic syndrome (MDS).
Lewis, Russell   +5 more
core   +1 more source

Refining the boundary between myelodysplastic neoplasm and chronic myelomonocytic leukaemia under World Health Organization 2022 criteria using open‐source data

open access: yes
British Journal of Haematology, EarlyView.
Jiwon Yun   +5 more
wiley   +1 more source

Mapping the omics landscape for peri‐implant diseases: A scoping review

open access: yesPeriodontology 2000, EarlyView.
Abstract Objectives To map omics evidence across peri‐implant health, peri‐implant mucositis, and peri‐implantitis, and to identify recurring molecular patterns and candidate biomarker signals relevant to diagnosis, monitoring, and treatment. Materials and Methods This scoping review included human studies using genomics, DNA methylation–based ...
Ethan Ng   +5 more
wiley   +1 more source

Response to venetoclax‐containing regimens in patients with relapsed/refractory (R/R) T‐cell acute lymphoblastic leukaemia (T‐ALL) and lymphoblastic lymphoma (T‐LBL)

open access: yes
British Journal of Haematology, EarlyView.
Miles Thomas   +6 more
wiley   +1 more source

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

open access: yesTransplant Infectious Disease, EarlyView.
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford   +32 more
wiley   +1 more source

Cross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications

open access: yesInternational Journal of Cancer, Volume 160, Issue 1, Page 7-23, 1 January 2027.
ABSTRACT Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states ...
Min Xing   +6 more
wiley   +1 more source

Pharmacoeconomic evaluation of hypomethylating agents used for the treatment of MDS

open access: yes, 2008
Introduction: Supportive care has traditionally been the primary treatment for patients with MDS. The approval of hypomethylating agents provides therapeutic options for these patients.
Franco, Carlos   +11 more
core   +1 more source

Identification of Crucial Drug Targets and Pathways to Reprogram Drug Resistance Through Epigenetic Modulation in Advanced Lung Cancer Using Integrated Bioinformatics Approach

open access: yesComputational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Resistance to chemotherapy, which is demonstrated in almost every patient with advanced‐stage lung cancer (ALC), underscores an urgent need to unravel the underlying molecular mechanisms and identify novel strategies to overcome drug resistance. In the present study, an attempt was made to identify epigenetic targets and modulators that can be
Okibur Rahman   +2 more
wiley   +1 more source

Established and novel agents for myelodysplastic syndromes

open access: yes, 2014
The myelodysplastic syndromes (MDS) are the most commonly diagnosed myeloid malignancy, with > 15 000 new cases identified in the United States yearly.
Sekeres, Mikkael A., Gerds, Aaron T.
core   +1 more source

Home - About - Disclaimer - Privacy